Cargando…
The FOXM1–ABCC5 axis contributes to paclitaxel resistance in nasopharyngeal carcinoma cells
Paclitaxel is clinically used as a first-line chemotherapeutic regimen for several cancer types, including head and neck cancers. However, acquired drug resistance results in the failure of therapy, metastasis and relapse. The drug efflux mediated by ATP-binding cassette (ABC) transporters and the s...
Autores principales: | Hou, Youxiang, Zhu, Qianling, Li, Zheng, Peng, Yongbo, Yu, Xiaohui, Yuan, Bowen, Liu, Yijun, Liu, Youhong, Yin, Linglong, Peng, Yuchong, Jiang, Zhenghua, Li, Jinping, Xie, Bowen, Duan, Yumei, Tan, Guolin, Gulina, Kurban, Gong, Zhicheng, Sun, Lunquan, Fan, Xuegong, Li, Xiong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5386553/ https://www.ncbi.nlm.nih.gov/pubmed/28277541 http://dx.doi.org/10.1038/cddis.2017.53 |
Ejemplares similares
-
FOXM1 contributes to taxane resistance by regulating UHRF1-controlled cancer cell stemness
por: Yuan, Bowen, et al.
Publicado: (2018) -
FOXM1 Promotes Drug Resistance in Cervical Cancer Cells by Regulating ABCC5 Gene Transcription
por: Hou, Youxiang, et al.
Publicado: (2022) -
PARP inhibitor veliparib and HDAC inhibitor SAHA synergistically co-target the UHRF1/BRCA1 DNA damage repair complex in prostate cancer cells
por: Yin, Linglong, et al.
Publicado: (2018) -
Correction to: PARP inhibitor veliparib and HDAC inhibitor SAHA synergistically co-target the UHRF1/. BRCA1 DNA damage repair complex in prostate cancer cells
por: Yin, Linglong, et al.
Publicado: (2022) -
Radiation-promoted CDC6 protein stability contributes to radioresistance by regulating senescence and epithelial to mesenchymal transition
por: Yu, Xiaohui, et al.
Publicado: (2018)